#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Search results: (10000)



News Effect of Etanercept on Structural Changes in the Sacroiliac Joint in Patients with Early Axial Spondyloarthritis

Currently, there is limited evidence regarding the effect of tumor necrosis factor inhibitors on structural lesions in patients with early forms of axial spondyloarthritis (AxSpA). The aim of the study presented below, published in January 2021, was to evaluate structural changes in the sacroiliac joint (SIJ) on magnetic resonance imaging (MRI) after 2 years of treatment with etanercept within the clinical study EMBARK in patients with early AxSpA compared to a control cohort not treated with biologics (DESIR) and to assess the relationship between MRI changes and disease activity according to ASDAS.
Source: Arthritis 14. 8. 2021

News Long-term results of alpha-1-antitrypsin deficiency treatment –⁠ RAPID program

RAPID/RAPID Extension is the largest clinical program to date that has confirmed the benefit of alpha-1-antitrypsin inhibitor in the treatment of chronic obstructive pulmonary disease (COPD) associated with its deficiency.
Source: Deficiency of Alpha-1-Antitrypsin 17. 12. 2020

Journal articles Highly active antiretroviral therapy during gestation: effects on a rat model of pregnancy

Author of the article: L. P. Carvalho, R. S. Simões, Edward Araujo Júnior, Oliveira Filho R. M., L. Kulay Júnior, M. U. Nakamura Source: Česká gynekologie | 2/2014 21. 4. 2014

News Sport and Physical Activity Benefit Hemophiliacs

Sport and physical activity are beneficial for individuals with hemophilia. This statement was confirmed by a study conducted by German and British authors published in the journal Haemophilia.
Source: Hemophilia 5. 5. 2021

Journal articles Global Allergy and Asthma European Network (GA2LEN) addresses the epidemic of allergy and asthma

Author of the article: Petr Panzner, Petr Čáp, Peter Burney, Torsten Zuberbier, Paul Van Cauvenberg, Jean Bousquet Source: Časopis lékařů českých | 1/2010 1. 1. 2010

News Efficacy of Romiplostim in Children with Persistent or Chronic ITP

The effect of the thrombopoietin receptor agonist romiplostim in adult patients with immune thrombocytopenia (ITP) is well known. Equally important, however, are data on its treatment in children —⁠ presented by a study whose results were published in the journal Lancet.
Source: Immune Thrombocytopenia 18. 11. 2020

News Liposomal Pegylated Irinotecan in the Treatment of Pancreatic Tumors

Combined treatment with liposomal pegylated irinotecan, 5-fluorouracil (5-FU), and leucovorin (LV) significantly improves overall survival in patients with metastatic ductal carcinoma of the pancreas. Analysis of the NAPOLI clinical trial revealed prognostic markers for long-term survival in patients treated this way.
Source: Treatment of Gastrointestinal Carcinomas 11. 5. 2021

News Genetic Testing in Non-Small Cell Lung Cancer -⁠ Clinical Practice Experience

Targeted therapy has brought significant improvements to certain groups of patients with non-small cell lung cancer (NSCLC). Selecting patients who will benefit from targeted therapy can be performed using molecular profiling with next-generation sequencing (NGS) techniques. However, we still lack sufficient data on the feasibility and results of such profiling in real-world clinical practice, which was the focus of an analysis recently published in The Oncologist.
Source: Genetic Profile and Treatment of NSCLC 30. 9. 2020

News Comparison of the effects of fibrinogen concentrates and fresh frozen plasma in patients with acute traumatic coagulopathy

A quasi-experimental study compared the effectiveness of fibrinogen concentrates and fresh frozen plasma in patients with severe blunt trauma requiring the administration of erythrocyte replacements.
Source: Life-threatening Bleeding 15. 6. 2022

News Nonacog Beta Pegol (N9-GP) in Bleeding Prophylaxis in Patients with Hemophilia B –⁠ Real World Data

The goal of hemophilia B treatment is currently the prevention of bleeding by administering a coagulation factor IX concentrate. The study presented below brings recent real-world data on treatment outcomes when switching to the latest preparation, nonacog beta pegol (N9-GP).
Source: Hemophilia with Movement 13. 6. 2023

News Maintenance treatment with oral olaparib in women with BRCA1/2 mutation and relapsed ovarian cancer

In a phase III study published in the journal Lancet Oncology, data on the effectiveness of olaparib in patients with ovarian cancer and BRCA1/2 mutation were evaluated. The poly(ADP-ribose) polymerase (PARP) inhibitor olaparib had previously demonstrated effectiveness in a phase II study in patients with prior sensitivity to platinum-based treatments.
Source: Ovarian and Breast Cancer 27. 4. 2020

News The role of the physiotherapist in hemophilia care is expanding and irreplaceable −⁠ what it entails and how it changes with treatment advances?

In the team cooperation in caring for patients with hemophilia, the physiotherapist plays a very important role, which is expanding with today's comprehensive approach to treating this condition. The reason is that even in the era of modern treatment availability, many hemophilia patients have various musculoskeletal complications. A team of authors, preferentially physiotherapists, recently published a paper pondering whether the advent of new drugs will also change the position of physiotherapy in the care of patients with hemophilia.
Source: Hemophilia with Movement 21. 11. 2022

News Manual Fascial Therapy in Patients with Hemophilic Arthropathy

Fascial therapy is a rehabilitative technique that mobilizes the fascial complex using manual techniques with the goal of improving tissue mobility and function, as well as influencing pain. A team of experts from Spain evaluated the safety of this method in hemophiliacs with developed arthropathy in their study.
Source: Hemophilia with Movement 22. 4. 2021

News Individualized Prophylaxis with Achieving Higher Minimum Levels as a Possible Path to Optimal Treatment of Hemophilia A

Prophylactic administration of factor VIII (FVIII) concentrate is the standard of care for individuals with severe hemophilia A. Traditionally, the goal of prophylaxis has been to maintain minimum FVIII levels > 1%. However, it has been shown that this goal may not protect many hemophiliacs from bleeding episodes. So how does prophylaxis that maintains higher FVIII levels stand? These insights were brought by the PROPEL study, whose results were recently published in Blood magazine.
Source: Hemophilia 15. 9. 2021

News Digital Technology in COPD Therapy: Current Options and Future Prospects

This year, digital technologies have demonstrated their advantages in interpersonal communication, administrative processes, and in the field of medicine. The global crisis triggered by the coronavirus pandemic revealed the need to implement telemedicine into everyday medical practice. What are its options and future prospects in the therapy of patients with chronic obstructive pulmonary disease? These questions are thoroughly addressed in an article published in the Journal of Thoracic Disease last fall.
Source: Treatment of Asthma and COPD 1. 9. 2020

News Mental Health During the Pandemic −⁠ and How to Alleviate Its Impacts

At the symposium during the XV Spring Interactive Conference of the General Medical Society of ČLS JEP, which was eventually held in September 2021 in Prague, Prof. MUDr. Cyril Höschl, DrSc., FRCPsych, presented his lecture on the impacts of the COVID-19 pandemic on mental health. At the end of his speech, he also addressed the practical issue of selecting a suitable antidepressant.
Source: Depression and Anxiety 10. 1. 2022

News Current Data on the Safety Profile of Baricitinib in the Treatment of Rheumatoid Arthritis

Baricitinib was approved for the treatment of rheumatoid arthritis (RA) in 2017, making it essential and relevant to monitor its safety profile in clinical practice. The analysis of data collected over 8.4 years presented below provides current insights.
Source: Biological Treatment 26. 10. 2020

News Administration of Romiplostim in Patients with ITP in Real-World Practice in Central Europe

Data from the PLATON study on the administration of romiplostim in real-world clinical practice in Central and Eastern Europe confirmed very good efficacy in patients with newly diagnosed, persistent, and chronic ITP.
Source: Immune Thrombocytopenia 11. 10. 2021

News How to Care for Dialysis Patients in the Times of COVID-19

More than 2 million people worldwide undergo maintenance hemodialysis in outpatient centers. Effective prevention of the spread of infection caused by the SARS-CoV-2 coronavirus within the care provided by hemodialysis centers is essential for the smooth provision of dialysis to patients with end-stage renal disease. The following work from experts in Boston is based on their experiences as well as recommendations from the American Society of Nephrology (ASN) and the Centers for Disease Control and Prevention (CDC).
Source: Chronic Kidney Disease 26. 1. 2021

News Efficacy and Safety of Teriflunomide in the Treatment of Multiple Sclerosis in Children –⁠ Results of the TERIKIDS Study

Therapeutic options for multiple sclerosis in the pediatric population are limited. However, in June 2021, teriflunomide was approved for the treatment of relapsing-remitting multiple sclerosis (RRMS) in pediatric patients aged 10–17 years in the European Union. The basis for this registration was the favorable results of the TERIKIDS study, which we summarize below. Teriflunomide thus became the first oral medication for 1st line treatment of RRMS in children and adolescents within the EU.
Source: Multiple Sclerosis 1. 6. 2022

News Use of Specific Inhibition of Anticoagulant Therapy During Heart Transplantation

A recent report from real clinical practice summarizes the experiences of physicians with dabigatran therapy and the reversal of its anticoagulant effect using idarucizumab in 10 patients before heart transplantation.
Source: Anticoagulant Treatment 1. 3. 2022

News Romiplostim in Newly Diagnosed ITP Resistant to 1st Line Treatment –⁠ Case Study

In patients with immune thrombocytopenia (ITP), effectively stopping and controlling bleeding can be complicated in some cases. This includes scenarios such as open wounds. One way to stabilize platelet count can be through administering a thrombopoietin receptor agonist (TPO-RA). The following case study presents a successful treatment of newly diagnosed ITP.
Source: Immune Thrombocytopenia 2. 10. 2023

News Quality of Life of Hemophiliacs and Ways to Improve It

Determining the quality of life (QoL) also reflects the morbidity associated with the disease, in this case, hemophilia. In the study presented below, the authors focused on determining QoL in relation to socioeconomic and other characteristics.
Source: Hemophilia with Movement 21. 5. 2021

News Webinar SGLT2i in ESC HF Guidelines vs. Real Practice

Dear Doctor, Boehringer Ingelheim, in collaboration with the 2nd Department of Internal Medicine -⁠ Department of Cardiology and Angiology, General University Hospital and 1st Faculty of Medicine, Charles University, cordially invites you to an online discussion to be held on Tuesday, November 23, 2021, from 5 : 00 PM to 6 : 30 PM. More information can be found in the attached invitation below.
Source: Heart Failure 18. 11. 2021

News What Are the Impacts of Not Administering Extended VTE Prophylaxis in Oncology Patients After GIT Surgeries?

In a freshly published retrospective study, experts from the University of Arkansas investigated how well the professional recommendation that cancer patients undergo extended venous thromboembolism (VTE) prophylaxis after major gastrointestinal (GI) surgeries is being followed and what impact this has in real practice.
Source: Thromboprophylaxis 28. 11. 2023

1 7 8 9 10 11 400
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#